Distinguishing Acute Kidney Injury from Chronic Kidney Disease

Initial Diagnostic Approach

The American Society of Nephrology recommends estimating a baseline creatinine using back-calculation from an assumed eGFR of 75 ml/min/1.73 m² to determine if AKI criteria are met, which is most accurate in younger patients with likely preserved kidney function 1, 2
A creatinine level of approximately 2.15 mg/dL represents significant renal dysfunction regardless of whether it's acute or chronic in a patient, such as a 45-year-old woman 3, 4
Using known creatinine values is always superior to imputation when available, so aggressively searching for any prior laboratory data is recommended 1, 2

Recent acute illness, sepsis, hypotension, or nephrotoxin exposure within the past 7-90 days favors AKI/AKD 5, 1
Normal to enlarged kidney size on ultrasound with preserved parenchymal thickness favors AKI/AKD 6
Small kidneys with reduced cortical thickness on ultrasound favors CKD 6
Anemia, hyperparathyroidism, or metabolic bone disease favors CKD 4
Long-standing hypertension, diabetes, or proteinuria documented previously favors CKD 4

AKD describes kidney dysfunction persisting between 7 and 90 days after an AKI-initiating event, and if dysfunction persists beyond 90 days, it transitions to CKD by definition 5, 1, 4
AKD can occur without meeting strict AKI criteria if the creatinine rise was gradual rather than abrupt 3

The Kidney International guidelines recommend ordering renal ultrasound to assess kidney size, echogenicity, and exclude obstruction 6
Obtaining urinalysis looking for proteinuria, hematuria, or cellular casts is recommended 7, 4
Reviewing medication list and discontinuing all nephrotoxins immediately is crucial 7, 8
Assessing volume status and optimizing hemodynamics is essential 5, 9
Searching exhaustively for any prior creatinine values in medical records is necessary 1, 2

Checking hemoglobin, calcium, phosphate, and parathyroid hormone to assess for chronicity is recommended 4
Measuring urine protein-to-creatinine ratio is necessary 7, 4
Serial creatinine measurements over 48-72 hours to determine trajectory is recommended 3

Planning nephrology follow-up within 7-14 days regardless of presumed diagnosis is necessary 9, 8
Monitoring kidney function for at least 90 days to distinguish AKD from CKD progression is essential 5, 1, 8

Not using standard eGFR equations designed for CKD to assess kidney function during the acute or subacute phase—they are inaccurate in this setting 8
Not discharging without a clear follow-up plan, as the 7-90 day window is critical for preventing progression to CKD 9, 8
Not recognizing that AKI and CKD frequently coexist, making pure categorization impossible in many cases 3

A creatinine rise of >3‑fold (e.g., from an estimated baseline of ~1.0–1.2 mg/dL to 4 mg/dL) meets the KDIGO AKI criteria in a middle‑aged adult with an assumed baseline GFR of 75 mL/min/1.73 m². 10
Acute Kidney Disease (AKD) is defined as kidney dysfunction persisting 7–90 days after an AKI‑initiating event; if dysfunction continues beyond 90 days it is re‑classified as CKD. 10
Patients may be in the AKD phase weeks after an unrecognized AKI episode, emphasizing the need to consider AKD even when AKI criteria are not strictly met. 11

Renal ultrasound should be performed immediately to exclude post‑renal obstruction, which accounts for <3 % of AKI cases but requires urgent intervention. 12
Avoid iodinated contrast in imaging studies unless absolutely necessary for a life‑threatening diagnosis. 12

Urinalysis is essential: muddy‑brown granular casts suggest acute tubular necrosis, while red‑blood‑cell casts point toward glomerulonephritis. 11
A normal hemoglobin level in the acute setting favors an AKI/AKD process, as anemia typically develops gradually in CKD. 12
Prior documentation of proteinuria or abnormal creatinine values supports a chronic kidney disease component. 12
A comprehensive metabolic panel helps identify metabolic acidosis and electrolyte disturbances associated with renal dysfunction. 12

Discontinue all nephrotoxic medications (e.g., NSAIDs, aminoglycosides, contrast agents, ACE inhibitors/ARBs in volume‑depleted patients) as soon as AKI/AKD is suspected. 11
Assess and optimize volume status and hemodynamics, correcting hypovolemia while avoiding fluid overload. 11
Review the medication list for drugs that require dose adjustment in the setting of reduced renal function. [10][11]

Arrange nephrology follow‑up within 7–14 days regardless of the presumed diagnosis.
Monitor kidney function for at least 90 days to differentiate AKD from progression to CKD. 10
Document the renal episode clearly in the medical record to facilitate future care continuity. 11

Do not rely on standard eGFR equations (MDRD, CKD‑EPI) during the acute phase, as they are inaccurate when serum creatinine is rapidly changing.
Do not discharge patients without a defined follow‑up plan, given the critical 7–90 day window for preventing progression to CKD.
Do not assume a purely acute or purely chronic process; acute‑on‑chronic kidney injury is common and associated with higher mortality and lower rates of renal recovery.
Do not depend solely on urine output for AKI diagnosis; serum creatinine remains the more reliable marker in the emergency setting. 12